TRANSFUSION AND APHERESIS SCIENCE, vol.49, no.3, pp.590-599, 2013 (SCI-Expanded)
Due to the high transplant related morbidity and mortality (TRM), relatively younger acute leukemia patients that have a good performance status and no comorbidity are eligible for myeloablative conditioning (MAC) followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT).